(Q33419346)

26 July 2017

title

Rituximab and bortezomib (RB): a new effective regimen for refractory or relapsed indolent lymphomas (English)

1 reference

26 July 2017

1 reference

Hou Yun

1

1 reference

26 July 2017

Hui Lai Zhang

series ordinal

2

1 reference

26 July 2017

Hua-Qing Wang

series ordinal

3

1 reference

26 July 2017

publication date

16 December 2014

1 reference

26 July 2017

1 reference

26 July 2017

volume

32

1 reference

26 July 2017

issue

1

1 reference

26 July 2017

page(s)

353

1 reference

Phase I trial of bortezomib (PS-341; NSC 681239) and "nonhybrid" (bolus) infusion schedule of alvocidib (flavopiridol; NSC 649890) in patients with recurrent or refractory indolent B-cell neoplasms

26 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS12032-014-0353-5

Rituximab plus a CHOP-like regimen, central nervous system prophylaxis, and contralateral testicular irradiation for localized primary testicular diffuse large B-cell lymphoma lead to prolonged progression-free survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-014-0353-5

Acquirement of rituximab resistance in lymphoma cell lines is associated with both global CD20 gene and protein down-regulation regulated at the pretranscriptional and posttranscriptional levels

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-014-0353-5

Bortezomib plus rituximab versus rituximab alone in patients with relapsed, rituximab-naive or rituximab-sensitive, follicular lymphoma: a randomised phase 3 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-014-0353-5

Bortezomib for the treatment of non-Hodgkin's lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-014-0353-5

Revised response criteria for malignant lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-014-0353-5

Phase II study of bortezomib in combination with rituximab, cyclophosphamide and prednisone with or without doxorubicin followed by rituximab maintenance in patients with relapsed or refractory follicular lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-014-0353-5

Results of a phase 2 study of bortezomib in patients with relapsed or refractory indolent lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-014-0353-5

Bortezomib, bendamustine, and rituximab in patients with relapsed or refractory follicular lymphoma: the phase II VERTICAL study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-014-0353-5

The combination of bendamustine, bortezomib, and rituximab for patients with relapsed/refractory indolent and mantle cell non-Hodgkin lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-014-0353-5

Ongoing Improvement in Outcomes for Patients Diagnosed as Having Non-Hodgkin Lymphoma From the 1990s to the Early 21st Century

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-014-0353-5

Addition of bortezomib to standard dose chop chemotherapy improves response and survival in relapsed mantle cell lymphoma

21 January 2018

1 reference

12 December 2020

Efficacy and toxicity of two schedules of bortezomib in patients with recurrent or refractory follicular lymphoma: a randomised phase II trial from the Groupe d'Etude des Lymphomes de l'Adulte (GELA)

1 reference

12 December 2020

In pursuit of a moving target: nanotherapeutics for the treatment of non-Hodgkin B-cell lymphoma

1 reference

12 December 2020

Indolent nonfollicular lymphomas: characteristics, treatment, and outcome.

1 reference

12 December 2020

Patterns of survival in patients with recurrent follicular lymphoma: a 20-year study from a single center

1 reference

12 December 2020

Promise of combining a Bcl-2 family inhibitor with bortezomib or SAHA for adult T-cell leukemia/lymphoma.

1 reference

12 December 2020

Preclinical evaluation of bortezomib/dipyridamole novel combination as a potential therapeutic modality for hematologic malignancies

1 reference

12 December 2020

10.1007/S12032-014-0353-5

Identifiers

DOI

1 reference

Dimensions Publication ID

26 July 2017

1017820602

0 references

1 reference